highli
pathogen
avian
influenza
hpai
virus
circul
among
poultri
popul
part
asia
africa
middl
east
caus
human
infect
high
mortal
rate
subtyp
hemagglutinin
ha
evolv
phylogenet
distinct
clade
subclad
base
virus
isol
variou
avian
speci
sinc
human
infect
hpai
virus
sever
clade
therefor
import
develop
strategi
produc
protect
antibodi
respons
virus
multipl
clade
antigen
group
current
studi
optim
signal
peptid
design
dna
vaccin
express
ha
antigen
virus
cross
reactiv
analysi
use
sera
immun
rabbit
show
antibodi
respons
elicit
polyval
formul
includ
ha
antigen
differ
clade
abl
elicit
broad
protect
antibodi
respons
multipl
key
repres
virus
across
differ
clade
data
present
report
support
develop
polyval
dna
vaccin
strategi
threat
potenti
influenza
pandem
continu
spread
highli
pathogen
avian
influenza
type
hpai
virus
avian
speci
across
multipl
contin
frequent
report
human
infect
china
southeast
asia
highlight
threat
potenti
flu
pandem
human
popul
time
virus
grown
genet
antigent
diversifi
virus
base
phylogenet
analysi
hemagglutinin
ha
protein
gene
sequenc
least
clade
virus
clade
identifi
recent
studi
assign
virus
four
major
antigen
group
ad
hpai
virus
one
clade
caus
human
infect
sinc
key
compon
global
strategi
prepar
control
pend
influenza
pandem
develop
effect
vaccin
sever
version
inactiv
well
live
attenu
vaccin
test
human
show
overal
good
safeti
immunogen
profil
mainli
use
clade
viru
vaccin
strain
per
recommend
world
health
organ
given
major
world
human
popul
influenza
two
immun
need
achiev
desir
level
protect
immun
respons
contrast
annual
season
flu
vaccin
requir
one
immun
presum
due
prime
effect
either
exposur
circul
type
b
influenza
virus
human
histori
prior
season
flu
vaccin
like
requir
two
immun
conjunct
genet
complex
virus
evidenc
separ
multipl
subgroup
make
difficult
prepar
time
product
suffici
number
dose
vaccin
event
pandem
therefor
supplement
strategi
need
shown
previous
publish
report
confirm
recent
studi
dna
primeinactiv
vaccin
boost
highli
effect
elicit
higher
protect
immun
respons
use
either
dna
inactiv
flu
vaccin
alon
therefor
may
possibl
use
dna
vaccin
first
dose
immun
given
either
long
pandem
prepandem
vaccin
shortli
outbreak
reduc
burden
product
inactiv
vaccin
time
outbreak
furthermor
dna
vaccin
stockpil
long
period
time
make
method
even
attract
one
key
issu
need
analyz
strategi
cross
reactiv
dna
vaccin
express
ha
antigen
differ
clade
critic
first
optim
immunogen
ha
dna
vaccin
test
much
cross
protect
achiev
optim
ha
dna
vaccin
current
report
construct
dna
vaccin
express
wild
type
ha
antigen
without
mutat
cleavag
site
four
key
strain
caus
major
human
infect
clade
clade
clade
clade
rabbit
sera
immun
ha
antigen
examin
protect
antibodi
respons
either
homolog
heterolog
virus
result
demonstr
imperfect
crossreact
profil
protect
antibodi
respons
among
four
virus
polyval
formul
includ
three
differ
ha
dna
vaccin
abl
produc
broad
protect
antibodi
respons
high
titer
key
isol
inform
learn
studi
facilit
select
candid
vaccin
form
polyval
dna
vaccin
part
global
strategi
prevent
control
potenti
avian
flu
pandem
one
key
find
previou
studi
ha
antigen
serotyp
differ
structur
prefer
order
elicit
optim
protect
antibodi
two
ha
antigen
design
use
studi
also
includ
current
studi
identifi
optim
design
serotyp
ha
antigen
one
use
wild
type
ha
antigen
insert
exact
amino
acid
sequenc
found
natur
viral
isol
use
truncat
ha
antigen
insert
remov
transmembran
tm
intracellular
segment
domain
fig
addit
third
ha
antigen
insert
creat
human
tissu
plasminogen
activ
tpa
sequenc
replac
origin
wild
type
leader
sequenc
ha
antigen
fig
third
ha
antigen
design
adopt
design
also
use
tpa
leader
sequenc
insert
serv
control
insert
understand
role
tpa
leader
incorpor
chang
design
origin
wild
type
ha
antigen
insert
order
maxim
immunogen
ha
dna
vaccin
shown
previou
studi
ha
gene
use
current
studi
also
codon
optim
chemic
synthes
addit
ha
gene
sequenc
use
current
studi
express
intact
ha
amino
acid
sequenc
cleavag
site
pqrexrrkkrqg
ha
protein
highli
pathogen
virus
cleavag
shown
import
pathogenesi
virus
inactiv
serotyp
flu
vaccin
residu
remov
improv
safeti
profil
vaccin
manufactur
mass
immun
purpos
express
immunogen
differ
form
dna
vaccin
code
ha
antigen
influenza
hong
kong
isol
first
set
ha
dna
vaccin
produc
clone
codon
optim
ha
gene
base
amino
acid
sequenc
ha
antigen
influenza
isol
respons
first
outbreak
avian
influenza
human
dna
vaccin
vector
express
ha
antigen
three
differ
dna
vaccin
examin
transient
transfect
cell
fig
regardless
whether
natur
ha
leader
tpa
leader
use
ha
protein
express
two
full
length
dna
vaccin
construct
hahkwt
hahktpa
detect
cell
lysat
supernat
suggest
mainli
cellassoci
contrast
truncat
ctermin
segment
includ
remov
tm
domain
dna
vaccin
construct
abl
significantli
increas
secret
ha
protein
detect
supernat
fig
ha
protein
express
three
ha
dna
vaccin
design
abl
cleav
subunit
fig
new
zealand
white
nzw
rabbit
use
current
studi
produc
larg
quantiti
sera
bind
antibodi
function
antibodi
analys
anim
immun
one
three
ha
dna
vaccin
individu
via
gene
gun
posit
antibodi
respons
elicit
immun
rabbit
sera
hk
ha
antigen
level
respons
increas
repeat
immun
neg
control
rabbit
group
receiv
empti
dna
vector
haspecif
antibodi
respons
fig
measur
tempor
peaklevel
antibodi
respons
differ
abil
three
form
ha
dna
vaccin
elicit
haspecif
antibodi
respons
fig
howev
function
antibodi
analys
rabbit
antiha
immun
sera
show
differ
pictur
sera
analyz
either
hemagglutin
inhibit
hi
microneutr
mn
assay
three
form
ha
dna
vaccin
induc
protect
antibodi
respons
autolog
wild
type
viru
level
protect
antibodi
differ
among
sera
induc
differ
design
ha
dna
vaccin
dna
vaccin
full
length
ha
insert
tpa
leader
sequenc
elicit
consist
higher
hi
mn
antibodi
titer
compar
two
form
hkha
insert
full
length
ha
natur
leader
sequenc
transmembran
region
tm
truncat
ha
differ
statist
signific
sera
base
hi
assay
fig
sera
base
mn
assay
fig
express
immunogen
differ
form
dna
vaccin
code
ha
antigen
isol
order
rule
find
uniqu
viru
isol
hong
kong
similar
design
ha
insert
produc
use
codon
optim
ha
dna
gene
strain
wellstudi
repres
isol
virus
pattern
ha
express
similar
ha
antigen
cellassoci
ha
antigen
detect
construct
contrast
identifi
ha
antigen
express
cell
lysat
supernat
fraction
fig
rabbit
immun
electropor
method
previous
report
similar
dna
plasmid
bind
antibodi
respons
measur
elisa
show
similar
level
among
sera
elicit
three
dna
vaccin
differ
ha
gene
insert
design
fig
howev
function
antibodi
measur
hi
mn
antibodi
analys
reveal
design
induc
highest
level
function
antibodi
respons
fig
case
function
antibodi
respons
wild
type
viru
differ
two
form
statist
signific
hi
mn
assay
order
ensur
differ
protect
antibodi
respons
sera
elicit
result
repeat
immun
sera
collect
one
three
immun
also
measur
fig
pseudotyp
virus
express
vn
ha
antigen
use
measur
neutral
antibodi
activ
rabbit
sera
less
immun
strength
protect
antibodi
measur
two
level
inhibit
concentr
block
either
viru
infect
target
cell
measur
show
rabbit
sera
significantli
higher
titer
neutral
antibodi
activ
wild
type
ha
design
especi
use
stringent
cutoff
fig
sensit
deglycosyl
treatment
ha
antigen
express
differ
form
ha
dna
vaccin
addit
studi
conduct
ask
glycosyl
ha
affect
use
differ
leader
sequenc
may
influenc
immun
respons
previou
studi
hepat
b
surfac
antigen
suggest
posttransl
modif
includ
glycosyl
may
affect
immunogen
dna
vaccin
deliv
antigen
asn
n
link
glycosyl
influenza
ha
protein
essenti
viru
infect
vaccin
immunogen
base
sequenc
analysi
nlink
glycosyl
site
asnxser
thr
ha
protein
next
investig
whether
ha
antigen
express
differ
design
ha
insert
dna
vaccin
similar
level
nlink
glycosyl
ha
antigen
express
cell
lysat
transfect
dna
vaccin
ha
antigen
express
cell
supernat
transfect
dna
vaccin
analyz
suscept
pngase
treatment
cleav
type
nlink
sugar
includ
complex
oligosaccharid
structur
result
matur
high
mannos
moieti
transport
glycoprotein
golgi
treatment
pngasef
allow
remov
nlink
glycosyl
shown
reduct
appar
molecular
weight
speci
western
blot
analysi
ha
protein
express
cell
transfect
ha
dna
vaccin
figur
molecular
weight
reduct
pattern
antigen
cell
transfect
dna
vaccin
suggest
ha
antigen
express
two
ha
dna
vaccin
similarli
glycosyl
smaller
molecular
weight
antigen
observ
cell
transfect
dna
vaccin
presum
due
truncat
size
domain
particular
ha
insert
design
howev
pngasef
treatment
also
led
proport
reduct
molecular
weight
truncat
protein
supernat
cell
lysat
prepar
uniqu
find
cellassoci
ha
antigen
transfect
cell
show
high
level
heterogen
small
portion
protein
fulli
deglycosyl
pngasef
treatment
reflect
continu
presenc
differ
form
glycosyl
ha
protein
transfect
cell
otherwis
overal
glycosyl
pattern
probe
deglycosyl
treatment
similar
among
ha
antigen
produc
three
differ
type
ha
dna
vaccin
crossprotect
antibodi
respons
induc
individu
dna
vaccin
express
ha
antigen
key
viral
isol
base
result
addit
ha
dna
vaccin
hatpa
insert
design
produc
use
codon
optim
ha
gene
encod
ha
protein
viral
strain
caus
human
infect
recent
year
given
circumst
influenza
antigen
drift
occur
sinc
first
human
outbreak
hong
kong
would
import
determin
ha
vaccin
develop
base
virus
isol
differ
epidem
time
point
induc
cross
antibodi
respons
virus
one
set
experi
conduct
understand
cross
protect
pair
ha
antigen
rabbit
immun
individu
dna
vaccin
rabbit
immun
sera
examin
ha
antigenspecif
antibodi
respons
haspecif
antibodi
respons
ha
antigen
differ
virus
analyz
elisa
potenti
crossprotect
antibodi
respons
differ
virus
evalu
hi
mn
assay
clade
isol
clade
isol
repres
virus
isol
first
human
outbreak
hong
kong
subsequ
outbreak
vietnam
respect
result
shown
fig
indic
dna
vaccineimmun
rabbit
sera
show
high
antibodi
respons
recogn
autolog
ha
antigen
heterolog
ha
antigen
howev
haspecif
igg
titer
autolog
antigen
higher
observ
heterolog
antigen
convers
dna
vaccin
elicit
high
level
haspecif
igg
respons
autolog
heterolog
ha
antigen
although
overal
titer
autolog
ha
antigen
may
higher
statist
signific
protect
hi
mn
antibodi
respons
induc
dna
vaccin
compar
either
wild
type
virus
fig
hi
mn
titer
present
hktpa
dna
vaccineimmun
rabbit
sera
similar
analysi
conduct
rabbit
immun
sera
elicit
ha
dna
vaccin
fig
clade
isol
repres
viru
isol
human
outbreak
china
cross
reactiv
immun
sera
virus
similar
observ
immun
sera
virus
bind
antibodi
respons
rabbit
immun
sera
significantli
higher
recognit
autolog
ha
antigen
heterolog
ha
antigen
rabbit
immun
sera
elicit
higher
antibodi
respons
recogn
autolog
ha
antigen
heterolog
ha
antigen
statist
signific
fig
function
antibodi
hi
mn
analys
show
prefer
rabbit
immun
sera
respect
autolog
wild
type
virus
fig
crossprotect
polyval
dna
vaccin
formul
express
ha
antigen
three
repres
viral
isol
result
indic
antibodi
respons
one
ha
antigen
viru
may
well
crossreact
anoth
ha
antigen
viru
level
antibodi
respons
autolog
antigen
viru
alway
higher
given
uncertainti
regard
viru
may
ultim
caus
pandem
outbreak
import
develop
vaccin
strategi
maxim
protect
efficaci
wide
spectrum
virus
differ
clade
subtyp
possibl
consensu
ha
antigen
structurallyoptim
ha
antigen
design
cover
differ
virus
variou
level
protect
efficaci
actual
data
show
ha
antigen
achiev
maximum
protect
antibodi
respons
sever
viral
isol
differ
clade
one
altern
approach
produc
polyval
ha
formul
includ
multipl
ha
dna
vaccin
one
inject
produc
immun
sera
induc
highest
antibodi
respons
wide
rang
viral
isol
pseudotyp
viru
system
develop
recent
year
wide
use
lead
influenza
studi
provid
high
sensit
detect
function
antibodi
respons
influenza
ha
antigen
time
elimin
influenc
influenza
viral
gene
product
sinc
common
viral
backbon
use
differ
ha
pseudotyp
virus
ideal
system
highthroughput
assay
multipl
serum
sampl
wide
rang
virus
shown
fig
rabbit
sera
elicit
either
ha
dna
vaccin
formul
monoval
ha
dna
vaccin
hk
vn
ah
test
antibodi
respons
three
pseudotyp
virus
express
ha
antigen
match
monoval
rabbit
sera
consist
show
highest
function
antibodi
respons
autolog
pseudotyp
virus
fig
howev
serum
one
show
high
level
antibodi
respons
three
pseudotyp
virus
one
nonmatch
monoval
rabbit
serum
could
neutral
one
two
virus
three
confirm
hypothesi
polyval
ha
formul
capabl
protect
multipl
virus
accord
phylogenet
analysi
virus
divid
clade
sinc
human
mainli
infect
virus
clade
although
also
report
infect
clade
viru
clade
complic
genet
evolut
divid
five
subclad
current
studi
progress
made
reduc
number
requir
immun
vaccin
inactiv
vaccin
incorpor
variou
adjuv
vaccin
formul
major
nextstep
vaccin
research
determin
degre
immun
elicit
one
avian
influenza
vaccin
current
mani
candid
vaccin
develop
base
clade
viru
crossprotect
virus
clade
unlik
human
type
influenza
virus
serotyp
potenti
pandem
caus
viru
avian
origin
theori
current
known
avian
virus
may
jump
human
popul
lead
next
pandem
therefor
system
examin
crossprotect
among
ha
antigen
differ
clade
need
strateg
plan
determin
whether
one
vaccin
need
base
analysi
protect
profil
particular
viral
strain
select
provid
maximum
breadth
protect
dna
vaccin
attract
strategi
provid
rel
quick
straightforward
product
vaccin
influenza
pandem
demand
vaccin
suddenli
increas
howev
key
issu
surround
use
dna
vaccin
low
immunogen
human
recent
year
success
primeboost
strategi
greatli
enhanc
util
dna
vaccin
futur
human
applic
time
optim
design
antigen
insert
base
uniqu
antigen
process
antigen
engin
also
play
key
role
result
includ
current
report
indic
tpa
leader
sequenc
ctermin
transmembran
domain
cytoplasm
region
ha
contribut
better
function
antibodi
respons
dna
vaccin
compar
dna
vaccin
find
differ
previou
result
protect
antibodi
respons
induc
differ
design
flu
ha
dna
vaccin
previou
studi
full
length
transmembran
truncat
induc
high
level
hi
mn
respons
viru
full
length
truncat
induc
similar
hi
mn
respons
viru
result
provid
strong
indic
ha
antigen
differ
influenza
subtyp
may
differ
prefer
antigen
structur
design
order
gener
optim
protect
antibodi
respons
studi
conduct
report
identifi
mechan
respons
better
protect
antibodi
rabbit
immun
sera
elicit
ha
insert
design
exact
mechan
current
unclear
first
test
whether
higher
level
ha
antigen
express
produc
tpalead
design
shown
fig
antigen
express
level
wtleader
design
tpalead
design
similar
thu
exclud
possibl
next
ask
whether
increas
secret
ha
antigen
due
use
tpa
leader
howev
shown
fig
major
detect
level
secret
ha
antigen
supernat
either
wtdesign
tpadesign
furthermor
dtm
design
higher
level
secret
due
delet
transmembran
intracellular
portion
ha
protein
elicit
better
protect
antibodi
respons
final
studi
conduct
examin
possibl
role
posttransl
process
chang
glycosyl
ha
antigen
may
affect
antigen
process
pathway
previous
report
hepat
b
surfac
antigen
dna
vaccin
howev
figur
show
major
differ
wtdesign
tpadesign
deglycosyl
treatment
therefor
like
ha
antigen
express
tpa
leader
may
effect
elicit
conform
antibodi
hypothesi
support
two
piec
evid
first
differ
level
bind
antibodi
measur
elisa
indic
differ
gener
immunogen
wt
tpa
leader
design
differ
function
antibodi
observ
second
hadtm
dna
vaccin
design
also
use
tpa
leader
better
function
antibodi
prove
proper
fold
ha
antigen
presenc
tpa
leader
import
depend
presenc
intact
domain
possibl
ha
antigen
conform
part
trimer
structur
ha
sinc
domain
involv
format
ha
trimer
antibodi
trimer
structur
function
relev
block
trimer
form
ha
spike
viral
particl
use
optim
ha
insert
design
studi
report
demonstr
good
level
cross
protect
one
ha
dna
vaccin
multipl
virus
differ
clade
well
document
cross
protect
among
virus
detect
clade
vaccin
vn
cross
protect
clade
clade
indonesia
virus
ferret
use
strong
adjuv
use
live
attenu
cold
adapt
ca
virus
express
ha
na
cross
protect
observ
late
viru
ferret
ferret
mice
mice
howev
shown
current
studi
ha
vaccin
elicit
level
cross
protect
antibodi
significantli
maximum
level
protect
antibodi
usual
detect
autolog
viral
isol
given
knowledg
protect
antiflu
antibodi
respons
human
much
rabbitsgroup
vector
hk
vn
ah
ind
group
rabbitsgroup
group
rabbit
sera
test
pseudotyp
nab
assay
collect
week
th
dna
immun
denot
detect
level
arrow
denot
neutral
autolog
pseudotyp
viru
statist
differ
test
group
autolog
neutral
group
group
indic
p
valu
less
lower
experiment
anim
cross
protect
may
high
human
one
randomli
select
ha
vaccin
current
set
studi
encourag
observ
polyval
ha
dna
vaccin
abl
elicit
high
level
protect
antibodi
respons
multipl
key
virus
polyval
flu
dna
vaccin
use
stockpil
potenti
pandem
even
inform
avail
viral
isol
may
caus
human
outbreak
time
altern
approach
includ
use
consensu
ha
antigen
design
achiev
broad
coverag
variou
viral
strain
person
commun
david
weiner
interest
compar
rel
efficaci
polyval
consensu
ha
dna
vaccin
abil
elicit
protect
antibodi
respons
one
uniqu
advantag
polyval
formul
flexibl
one
altern
ha
antigen
replac
ad
earlier
polyval
formul
event
new
strain
viru
becom
threat
necessari
redesign
whole
consensu
ha
insert
order
allow
broader
coverag
hi
titer
heterolog
viru
crossclad
significantli
reduc
compar
hi
titer
homolog
viru
current
studi
heterolog
viru
titer
gener
human
hi
titer
associ
protect
construct
might
protect
multipl
immun
time
titer
observ
mice
may
human
hi
titer
associ
protect
ha
dna
vaccin
describ
current
report
test
protect
challeng
possibl
construct
may
protect
clinic
diseas
lethal
infect
matter
design
dna
vaccin
may
use
recent
studi
indic
dna
prime
immun
effect
part
prime
boost
strategi
flu
vaccin
applic
addit
dna
primeinactiv
flu
vaccin
boost
studi
publish
demonstr
dna
primel
attenu
flu
vaccin
boost
equal
effect
twice
immun
live
attenu
flu
vaccin
virus
base
antibodi
respons
viral
clearanc
immun
ferret
sinc
live
attenu
vaccin
consid
immunogen
form
vaccin
impress
observ
one
time
dna
prime
abl
achiev
prime
effect
live
attenu
flu
vaccin
particular
studi
dna
insert
use
part
collabor
manufactur
live
attenu
flu
vaccin
base
result
publish
current
report
recent
similar
studi
ha
dna
vaccin
evalu
current
studi
includ
design
human
studi
understand
whether
result
report
reproduc
human
use
part
dna
prime
either
individu
part
polyval
ha
dna
formul
find
studi
use
identif
simpl
yet
power
approach
develop
vaccin
major
influenza
pandem
prefer
homo
sapien
less
optim
codon
ha
gene
chang
prefer
codon
mammalian
system
promot
higher
express
ha
protein
previous
describ
codon
optim
ha
gene
chemic
synthes
geneart
regensburg
germani
ad
restrict
enzym
site
psti
bamhi
subclon
purpos
immedi
upstream
start
codon
downstream
stop
codon
respect
either
ha
dna
vaccin
three
version
codon
optim
ha
gene
insert
clone
dna
vaccin
vector
first
version
full
length
ha
gene
insert
aa
natur
ha
leader
sequenc
subclon
individu
vector
psti
bamhi
site
design
dna
vaccin
construct
second
version
ha
natur
leader
sequenc
first
aa
nterminu
replac
human
tissu
plasminogen
activ
tpa
leader
sequenc
ha
gene
insert
code
aa
pcr
amplifi
full
length
codon
optim
ha
gene
use
follow
primer
gtcgctccgctagc
gaccagatctgcatcggctac
agtcacggatcc
tcagatgcagatccggcactg
individu
ha
gene
clone
vector
nhei
bamhi
site
downstream
tpa
leader
sequenc
design
dna
vaccin
construct
third
version
ha
natur
leader
sequenc
replac
tpa
leader
sequenc
transmembran
tm
cytoplasm
region
aa
cterminu
ha
delet
truncat
ha
gene
pcr
amplifi
full
length
codon
optim
ha
gene
use
primer
pair
agtcac
ggatcctcactggtaggtgcccatgctctc
agtcacggatcctcactggtagatgccgatgctttc
respect
truncat
gene
insert
individu
clone
vector
nhei
bamhi
site
downstream
tpa
leader
sequenc
design
ha
dna
vaccin
construct
full
length
ha
tpalead
sequenc
made
describ
individu
dna
vaccin
plasmid
prepar
escherichia
coli
strain
mega
purif
kit
qiagen
valencia
ca
vitro
transfect
vivo
anim
immun
studi
nzw
rabbit
kg
bodi
weight
purchas
millbrook
breed
lab
amherst
immunogen
studi
hous
depart
anim
medicin
univers
massachusett
medic
school
accord
iacuc
approv
protocol
rabbit
rabbitsgroup
immun
helio
gene
gun
biorad
shave
abdomin
skin
previous
report
total
mg
ha
dna
vaccin
plasmid
vector
control
plasmid
immun
dna
immun
given
week
serum
sampl
taken
prior
first
immun
week
immun
studi
haspecif
antibodi
respons
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
protocol
approv
univers
massachusett
medic
school
institut
anim
use
care
committe
iacuc
protocol
surgeri
perform
sodium
pentobarbit
anaesthesia
effort
made
minim
suffer
transient
express
ha
antigen
variou
ha
dna
vaccin
construct
verifi
western
blot
analysi
ha
dna
vaccin
construct
first
transfect
human
embryon
kidney
cell
use
calcium
phosphat
precipit
method
briefli
cell
confluenc
mm
dish
transfect
mg
plasmid
dna
total
ml
supernat
ml
cell
lysat
harvest
hour
later
equal
amount
transient
express
ha
antigen
ng
protein
ml
load
sdspolyacrylamid
gel
electrophoresi
sdspage
denatur
condit
transfer
onto
pvdf
membran
biorad
hercul
ca
block
overnight
block
buffer
iblock
membran
incub
dilut
rabbit
sera
immun
ha
dna
vaccin
min
follow
wash
membran
incub
alkalin
phosphataseconjug
goat
antirabbit
igg
dilut
min
follow
wash
signal
detect
use
chemiluminescencebas
westernlight
kit
tropix
bedford
analyz
nlink
glycosyl
ha
antigen
express
variou
form
ha
dna
vaccin
ha
antigen
express
cell
treat
pngasef
new
england
biolab
beverli
briefli
ha
protein
first
denatur
min
glycoprotein
denatur
buffer
chill
ice
follow
addit
reaction
buffer
deglycosyl
enzym
cocktail
ad
incub
reaction
hour
either
mocktreat
deglycosyl
ha
sampl
subject
sdspage
western
blot
analysi
perform
describ
elisa
conduct
measur
haspecif
antibodi
igg
respons
immun
rabbit
mice
flatbottom
plate
coat
ml
cona
mgml
hour
room
temperatur
wash
time
pb
contain
triton
subsequ
plate
incub
overnight
ml
transient
express
ha
antigen
mg
ml
wash
time
plate
block
mlwell
block
buffer
nonfat
dri
milk
whey
pb
hour
five
wash
ml
serial
dilut
rabbit
mous
serum
ad
duplic
well
incub
hour
anoth
set
wash
plate
incub
hour
ml
biotinyl
antirabbit
antimous
igg
vector
laboratori
burlingam
ca
dilut
whey
dilut
buffer
whey
pb
ml
horseradish
peroxidaseconjug
streptavidin
vector
laboratori
dilut
whey
buffer
ad
well
incub
hour
final
wash
plate
develop
tetramethybenzidin
tmb
solut
ml
per
well
sigma
st
loui
mo
minut
reaction
stop
ad
ml
h
plate
read
od
nm
end
titrat
titer
determin
highest
serum
dilut
od
read
twice
neg
control
serum
influenza
virus
aviet
grown
allanto
caviti
embryon
hen
egg
h
allanto
fluid
pool
multipl
egg
clarifi
centrifug
frozen
aliquot
egg
infecti
dose
viru
stock
calcul
method
reed
muench
follow
serial
titrat
egg
experi
hpai
virus
conduct
biosafeti
level
contain
hemagglutinationinhibit
hi
assay
hi
assay
perform
standard
method
briefli
assay
perform
use
vv
fowl
hors
red
blood
cell
ha
unit
refer
viru
ahongkong
aindonesia
specif
sera
treat
receptor
destroy
enzym
hi
titer
defin
highest
dilut
serum
abl
inhibit
hemagglutin
mn
assay
perform
describ
previous
brief
influenza
viru
contain
tcid
incub
equal
volum
twofold
dilut
specif
heatinactiv
serum
overnight
humidifi
atmospher
hr
incub
ml
virusserum
sampl
ad
plate
contain
madin
darbi
canin
kidney
mdck
cell
monolay
incub
day
microneutr
titer
defin
highest
dilut
serum
neutral
tcid
viru
mdck
cell
cultur
detect
absenc
cytopath
effect
mn
assay
conduct
two
differ
lab
nation
microbiolog
laboratori
public
health
agenc
canada
beij
institut
microbiolog
epidemiolog
accord
virus
avail
recombin
lentivir
vector
express
luciferas
report
gene
produc
previous
describ
produc
pseudotyp
virus
cell
cell
plate
day
transfect
mg
pnl
nih
aid
refer
reagent
program
mg
dna
vaccin
plasmid
mg
plasmid
use
mg
polyetheleneimin
transfect
reagent
supernat
harvest
hour
later
frozen
standard
infect
cell
use
luciferasebas
measur
neutral
assay
serum
sampl
ml
heat
inactiv
minut
threefold
serial
dilut
cultur
medium
flatbottom
microtit
plate
pseudotyp
virion
ad
plate
incub
hour
incub
cell
trypsin
ad
plate
dilut
cell
per
well
follow
incub
plate
develop
use
luciferas
assay
system
promega
valu
averag
triplic
well
use
determin
base
well
display
reduct
infect
compar
control
well
contain
viru
plu
preimmun
sera
